Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
Phase 2
Terminated
- Conditions
- Dystrophic Epidermolysis BullosaJunctional Epidermolysis Bullosa
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Lenus Therapeutics, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT03578029
- Locations
- 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
News
No news found